Bayer's anti-cancer drug regorafenib shows stabilization or regression in 81% of kidney cancer patients
Thursday, September 24, 2009 16:00 IST Berlin
Bayer Schering Pharma AG, Germany, announced results from a phase-II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 per cent
